- Home
- PCQ vs ITRM Comparison
PCQ vs ITRM Comparison
Compare PCQ & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCQ
- ITRM
- Stock Information
- Founded
- PCQ 2001
- ITRM 2015
- Country
- PCQ United States
- ITRM Ireland
- Employees
- PCQ N/A
- ITRM N/A
- Industry
- PCQ Investment Managers
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- PCQ Finance
- ITRM Health Care
- Exchange
- PCQ Nasdaq
- ITRM Nasdaq
- Market Cap
- PCQ N/A
- ITRM 40.0M
- IPO Year
- PCQ N/A
- ITRM 2018
- Fundamental
- Price
- PCQ $8.65
- ITRM $0.97
- Analyst Decision
- PCQ
- ITRM Strong Buy
- Analyst Count
- PCQ 0
- ITRM 2
- Target Price
- PCQ N/A
- ITRM $7.00
- AVG Volume (30 Days)
- PCQ 69.6K
- ITRM 501.9K
- Earning Date
- PCQ 01-01-0001
- ITRM 08-13-2025
- Dividend Yield
- PCQ 4.63%
- ITRM N/A
- EPS Growth
- PCQ N/A
- ITRM N/A
- EPS
- PCQ N/A
- ITRM N/A
- Revenue
- PCQ N/A
- ITRM N/A
- Revenue This Year
- PCQ N/A
- ITRM N/A
- Revenue Next Year
- PCQ N/A
- ITRM $270.19
- P/E Ratio
- PCQ N/A
- ITRM N/A
- Revenue Growth
- PCQ N/A
- ITRM N/A
- 52 Week Low
- PCQ $8.19
- ITRM $0.81
- 52 Week High
- PCQ $10.50
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- PCQ 65.21
- ITRM 45.02
- Support Level
- PCQ $8.35
- ITRM $0.93
- Resistance Level
- PCQ $8.47
- ITRM $1.03
- Average True Range (ATR)
- PCQ 0.07
- ITRM 0.04
- MACD
- PCQ 0.03
- ITRM 0.00
- Stochastic Oscillator
- PCQ 88.24
- ITRM 29.23
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.